Related references
Note: Only part of the references are listed.Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients
Y. Gonzalez-Lama et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Thiopurine metabolite measurement - not for everyone
D. P. van Asseldonk et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-Proceedings of the first Thiopurine Task Force meeting
Dirk P. van Asseldonk et al.
DIGESTIVE AND LIVER DISEASE (2011)
Clinical Usefulness of Therapeutic Drug Monitoring of Thiopurines in Patients with Inadequately Controlled Inflammatory Bowel Disease
Melissa L. Haines et al.
INFLAMMATORY BOWEL DISEASES (2011)
Use of Thiopurine Testing in the Management of Inflammatory Bowel Diseases in Clinical Practice: A Worldwide Survey of Experts
Xavier Roblin et al.
INFLAMMATORY BOWEL DISEASES (2011)
Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
L. J. J. Derijks et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Thiopurine Therapy in Inflammatory Bowel Disease Patients: Analyses of Two 8-Year Intercept Cohorts
B. Jharap et al.
INFLAMMATORY BOWEL DISEASES (2010)
Thiopurine Maintenance Therapy for Ulcerative Colitis: The Clinical Significance of Monitoring 6-Thioguanine Nucleotide
Hiroyuki Hanai et al.
INFLAMMATORY BOWEL DISEASES (2010)
Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease
L. Y. Kwan et al.
DIGESTIVE AND LIVER DISEASE (2008)
The role of xanthine oxidase in thiopurine metabolism: A case report
Dennis R. Wong et al.
THERAPEUTIC DRUG MONITORING (2007)
Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism
Nanne K. H. de Boer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease:: results from a randomized, controlled, open trial
Max Reinshagen et al.
CLINICAL CHEMISTRY (2007)
Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease
L. P. L. Gilissen et al.
DIGESTIVE AND LIVER DISEASE (2007)
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis
MT Osterman et al.
GASTROENTEROLOGY (2006)
Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations
AFY Al Hadithy et al.
DIGESTIVE AND LIVER DISEASE (2005)
The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease
BA Goldenberg et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease
S Wright et al.
GUT (2004)
Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease
JP Achkar et al.
INFLAMMATORY BOWEL DISEASES (2004)
Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease
U Hindorf et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2004)
Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy
LJJ Derijks et al.
THERAPEUTIC DRUG MONITORING (2004)
Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy
LPL Gilissen et al.
CLINICAL DRUG INVESTIGATION (2004)
Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis
S Kane et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Drug interaction between infliximab and azathioprine in patients with Crohn's disease
X Roblin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine
BA Kaskas et al.
GUT (2003)
Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease
A Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease
M Regueiro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2002)
TPMT in the treatment of Crohn's disease with azathioprine
L Lennard
GUT (2002)
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2002)
Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine
S Campbell et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease
PW Lowry et al.
GUT (2001)
6-mercaptopurine metabolite levels in children with inflammatory bowel disease
P Gupta et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2001)
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
C Cuffari et al.
GUT (2001)
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease
J Belaiche et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2001)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2000)
Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance
EY Krynetski et al.
PHARMACOLOGY (2000)
Share Paper
